Advertisement
| car t cell therapy janssen: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t cell therapy janssen: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t cell therapy janssen: Digital Economy. Emerging Technologies and Business Innovation Rim Jallouli, Mohamed Anis Bach Tobji, Deny Bélisle, Sehl Mellouli, Farid Abdallah, Ibrahim Osman, 2019-09-20 This book constitutes the refereed proceedings of the 4th International Conference on Digital Economy, ICDEc 2019, held in Beirut, Lebanon, in April 2019. The conference was founded in 2016 to discuss innovative research and projects related to the support role of Information System Technologies in the digital transformation process, business innovation and e-commerce. The 31 papers presented in this volume were carefully reviewed and selected from 89 submissions. The theme of ICDEc 2019 was “Digital Economy: Emerging Technologies and Business Innovation”. The papers were organized in topical sections named: digital transformation; e-finance; social media communication; intelligent systems; e-commerce and business analytics; e-learning and cloud education; e-commerce and digital economy; data science; digital marketing; and digital business model. |
| car t cell therapy janssen: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t cell therapy janssen: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t cell therapy janssen: Career Options for Biomedical Scientists Kaaren A. Janssen, Richard Sever, 2015 Most people who do a PhD and postdoctoral work in the biomedical sciences do not end up as principal investigators in a research lab. Despite this, graduate courses and postdoctoral fellowships tend to focus almost exclusively on training for bench science rather than other career paths. This book plugs the gap by providing information about a wide variety of different careers that individuals with a PhD in the life sciences can pursue. Covering everything from science writing and grant administration to patent law and management consultancy, the book includes firsthand accounts of what the jobs are like, the skills required, and advice on how to get a foot in the door. It will be a valuable resource for all life scientists considering their career options and laboratory heads who want to give career advice to their students and postdocs. |
| car t cell therapy janssen: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car t cell therapy janssen: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t cell therapy janssen: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t cell therapy janssen: Economic Dimensions of Personalized and Precision Medicine Ernst R. Berndt, Dana P. Goldman, John Rowe, 2019-04-22 Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement of PPM is a challenge in traditional clinical, reimbursement, and regulatory landscapes because it is costly to develop and introduces a wide range of scientific, clinical, ethical, and socioeconomic issues. PPM raises a multitude of economic issues, including how information on accurate diagnosis and treatment success will be disseminated and who will bear the cost; changes to physician training to incorporate genetics, probability and statistics, and economic considerations; questions about whether the benefits of PPM will be confined to developed countries or will diffuse to emerging economies with less developed health care systems; the effects of patient heterogeneity on cost-effectiveness analysis; and opportunities for PPM’s growth beyond treatment of acute illness, such as prevention and reversal of chronic conditions. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. |
| car t cell therapy janssen: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| car t cell therapy janssen: Why We Revolt Victor Montori, 2020-09-29 The Mayo Clinic physician and founder of The Patient Revolution offers a “thoroughly convincing. . . call to action for medical industry reform” (Kirkus). Winner of the 2018 PenCraft Award for Literary Excellence, Why We Revolt exposes the corruption and negligence that are endemic in America’s healthcare system—and offers a blueprint for revolutionizing patient care across the country. Through a series of essays and first-hand accounts, Dr. Victor M. Montori demonstrates how the system has been increasingly exploited and industrialized, putting profit before patients. As costs soar, the United States continues to fall behind other countries on patient outcomes. Offering concrete, direct actions we can take to bring positive change to the healthcare system, Why We Revolt is an inspiring call-to-action for physicians, policymakers, and patients alike. Dr. Montori shows how we can work together to create a system that offers tailored healthcare in a kind and careful way. All proceeds from Why We Revolt go directly to Patient Revolution, a non-profit organization founded by Dr. Montori that empowers patients, caregivers, community advocates, and clinicians to rebuild our healthcare system. |
| car t cell therapy janssen: Myeloid Derived Suppressor Cells as Disease Modulators Olivera J. Finn, Augusto C. Ochoa, 2020-05-06 Myeloid Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that can suppress the function of multiple immune cells and in particular, T cells, through various mechanisms. MDSCs can be divided into two major subtypes based on their cell surface phenotype and morphology: polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC). Additional subtypes have been proposed, such as the early MDSC (e-MDSC) that lack both macrophage and granulocyte markers. There is still considerable ambiguity about the phenotype of these cells that corresponds to their immunosuppressive function and there are on-going challenges on how to identify, purify and/or potentially generate and expand these cells in vitro. MDSCs were first discovered in cancer patients where they have been most extensively studied as components of the immunosuppressive tumor microenvironment. In the last several years, however, the importance of their immunomodulatory role in many other disease and clinical settings has emerged. Acknowledgments We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS. |
| car t cell therapy janssen: Resistance to Targeted Therapies in Lymphomas Ana C. Xavier, Mitchell S. Cairo, 2019 This volume will review different classes of target drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era. |
| car t cell therapy janssen: Minimal Residual Disease Testing Todd E. Druley, 2018-11-15 This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of difference from normal flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice. |
| car t cell therapy janssen: Canadian Immunization Guide Canada. Comité consultatif national de l'immunisation, Canada. National Advisory Committee on Immunization, 2006 The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization. |
| car t cell therapy janssen: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| car t cell therapy janssen: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t cell therapy janssen: Canadian Occupational Performance Measure Mary Law, Canadian Association of Occupational Therapists, 1998 Developed to help occupational therapists learn to use the COPM. Provides a self-directed program which allows learning at your own pace, links reference materials in a step-by-step fashion, and demonstrates examples and clinical scenarios. |
| car t cell therapy janssen: Kidney Cancer Primo N. Lara, Eric Jonasch, 2015-06-10 Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recent developments in kidney cancer diagnosis and therapy. The user-friendly and clinically oriented content of the book guarantees that it will be of great interest to a wide range of medical professionals, and every effort has been made to ensure that contributions are both easy to understand and directly related to patient care. Content presentation departs from the usual dense chapter format featuring a lengthy series of paragraphs. Instead, each chapter contains several boxed sections, including one that summarizes essential take home points for the busy clinician and another that presents a patient-oriented case highlighting the clinical application of elements discussed in that chapter. In addition, accessible original images, illustrations, and diagrams (some in full color) are used to simplify particularly complex material. This book will be of value for clinicians, researchers, residents, fellows, students, and knowledgeable lay people. The contributors comprise an international group of authors with expertise in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others. |
| car t cell therapy janssen: Innovations in Development, Translational Research and Manufacturing of CAR T cells Michael Hudecek, Qasim Rafiq, Stephen Goldrick, Ulrike Koehl, Helene Negre, Carmen Sanges, 2024-10-03 Immunotherapy with genetically engineered immune cell products is a transformative treatment modality with potential applications in various fields of medicine. A prime example is chimeric antigen receptor (CAR)-modified T cells in hematology and oncology, and the advent of CAR T cell therapies to treat infectious diseases, autoimmune disorders, and cardiovascular diseases. The medical need and demand from patients and caregivers require radical innovations to accelerate and improve pre-clinical development and clinical translation, provision of gene-transfer vectors, and immune cell product manufacturing as well as a critical reflection and discussion on ethical and socioeconomic aspects. The goal of this special issue of Frontiers in Immunology is to provide a comprehensive and multi-faceted view on the current state-of-the-art, imminent and future directions the field is taking in order to accelerate the pre-clinical development, clinical translation, and manufacturing of CAR T cells, increase access and sustainability of CAR T cell therapy for health care systems (in developed and in developing countries). This special issue will focus on the medical and scientific dimension incl. approved and emerging indications, new areas in medicine, advanced gene-transfer and gene-editing technologies, innovations in pre-clinical assessment (efficacy, toxicology, genomic safety), innovations in scalable automated manufacturing (bioprocessing), the implementation of high content data acquisition, machine learning and artificial intelligence, innovations in clinical trial design; and consider the ethical, socioeconomic and societal dimension of CAR T cells in particular and gene-engineered immune cell therapy in general. |
| car t cell therapy janssen: Second Generation Cell and Gene-Based Therapies Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi, 2020-02-07 Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products.The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. - Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization - Perspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights - Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies |
| car t cell therapy janssen: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| car t cell therapy janssen: Advances In Pharmaceutical Cell Therapy: Principles Of Cell-based Biopharmaceuticals Christine Guenther, Andrea Josefine Hauser, Ralf Huss, 2015-09-23 This textbook is a comprehensive overview of the development of cell-based biopharmaceuticals. Beginning with the underlying biology of stem cell and cell-based products, it traces the long and complex journey from preclinical concept to initiation of a pivotal clinical trial and the potential business model behind it.The book also takes into consideration the different regulatory landscapes and their continuous evolution in Europe, North America and other parts of the world. The authors describe a path to manufacture a clinical grade therapeutic that passes all necessary quality measures as a robust and marketable product including an outlook on next generation products and innovative strategies.This reference book is a must-have guide for any professional already active in biopharmaceuticals and anyone interested in getting involved in a scientific, medical or business capacity. |
| car t cell therapy janssen: American Society of Hematology Self-Assessment Program Timothy Graubert, James R. Cook, Laura Scheuttpelz, Donald M. Arnold, Adam Cuker, Cindy Neunert, Keith R. McCrae, Margaret Ragni, Sarah O'Brien, Murat Arcasoy, Gary Lyman, Marc J. Kahn, Lawrence A. Solberg, Jecko Thachil, Timothy James Littlewood, Sioban Keel, Charles T. Quinn, Charles H. Packman, Stephan Moll, David Garcia, David P. Steensma, Anjali Sharathkumar, Jorge Di Paola, Amy D. Shapiro, A. Koneti Rao, Charles Eby, Jacob Rand, John Frater, Karen Quillen, Suzanne Bakdash, Dan S. Kaufman, David T. Scadden, Jerald Radich, Sergio Giralt, Geoffrey L. Uy, Inderjeet Dokal, Ross Levine, Ramon V. Tiu, Phillip Scheinberg, Lillian Sung, B. Douglas Smith, Daniel J. DeAngelo, Ching-Hon Pui, Kristie A. Blum, Ann LaCasce, Kerry Joanne Savage, Brad S. Kahl, Grzegorz S. Nowakowski, Vicki A. Morrison, Irene Ghobrial, Martha Lacy, 2013-06-04 Hematologists and others working in hematology-related fields need to stay current with the latest advances in the rapidly evolving disciplines of adult and pediatric hematology. The American Society of Hematology Self-Assessment Program (ASH-SAP) is the only complete, comprehensive, educational resource available that fulfills this need, while also providing thorough board and recertification preparation, as well as AMA PRA Category 1 Credit'. |
| car t cell therapy janssen: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| car t cell therapy janssen: Management of Hematologic Malignancies Susan O'Brien, Julie M. Vose, Hagop M. Kantarjian, 2010-11-18 Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology. |
| car t cell therapy janssen: Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist Valerie I. Brown, 2017-12-22 This volume provides a comprehensive and state-of-the-art review on pediatric hematopoietic stem cell transplantation (HSCT). The book covers such topics as graft versus host disease (GVHD), HSC mobilization, stem cell selection, and HSCT-relevant laboratory assays and techniques. The text is specially formatted so that the scientific basis of HSCT and ethical considerations are integrated into the relevant clinical framework. Each chapter also includes diagrams, illustrations, and tables that summarize key points and concepts that can be used as a quick visual reference for the reader. Written by experts in the field, Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist is a valuable resource on pediatric HSCT suited for pediatric hematologists-oncologists, fellows, advanced practitioners, clinical nurses, and other referring physicians. |
| car t cell therapy janssen: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t cell therapy janssen: Advancing Healthcare Through Personalized Medicine Priya Hays, 2021-09-27 This book provides a unique perspective on the biomedical and societal implications of personalized medicine and how it helps to mitigate the healthcare crisis and rein in ever-growing expenditure. It introduces the reader to the underlying concepts at the heart of personalized medicine. An innovative second edition, this book functions as an update to the successful first edition to include new, state-of-the-art information and advancements in the fast-paced field of personalized medicine. Chapters examine pharmacogenomics, targeted therapies, individualized diagnosis and treatment, and cancer immunotherapies. The book also features an essential discussion on how the advent of genomic technologies gives clinicians the capability to predict and diagnose disease more efficiently and offers a detailed up-to-date compilation of clinical trials in cancer leading to breakthrough therapies. The book also addresses the impact of Big Data on personalized medicine and the newfound applications of digital health and artificial intelligence. A work that advocates for a patient-centered approach, Advancing Healthcare Through Personalized Medicine, Second Edition is an invaluable text for clinicians, healthcare providers, and patients. |
| car t cell therapy janssen: Ovarian Cancers National Academies of Sciences, Engineering, and Medicine, Institute of Medicine, Board on Health Care Services, Committee on the State of the Science in Ovarian Cancer Research, 2016-04-25 In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers. |
| car t cell therapy janssen: Clinical Guide to Antineoplastic Therapy Mary Magee Gullatte, 2014 Get the latest information on antineoplastic use and patient care when you purchase your copy of the essential chemotherapy resource for cancer-care professionals. Newly updated, revised, and expanded, the third edition of the Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook serves as an up-to-date reference for clinicians at every level from students and novices to the most seasoned nurses and other healthcare professionals involved in the care of patients receiving chemotherapy. Edited by Mary Magee Gullatte, this comprehensive guide features chapters on the fundamentals of antineoplastic therapy, commonly used regimens for specific cancers, clinical trials, reimbursement for chemotherapy, botanicals and other complementary and alternative therapies, vascular access devices, and symptom management, as well as an easy-to-use A Z guide of more than 150 chemotherapy, biotherapy, and hormonal therapy agents. New to this edition are chapters on patient navigati |
| car t cell therapy janssen: WHO List of Priority Medical Devices for Cancer Management World Health Organization, 2017-05-09 This is the model list and clearing house of appropriate, basic, and priority medical devices based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring, and end of life care. This publication addresses medical devices that can be used for the management of cancer and specifically describes medical devices for six types of cancer: breast, cervical, colorectal, leukemia, lung, and prostate. This book is intended for ministries of health, public health planners, health technology managers, disease management, researchers, policy makers, funding, and procurement agencies and support and advocacy groups for cancer patients. |
| car t cell therapy janssen: New Frontiers in Gene-Modified T Cell Technology Ignazio Caruana, Francesca Del Bufalo, Rayne Rouce, Shigeki Yagyu , Paul G. Schlegel, 2024-06-13 The development, clinical translation and recent efficacy of novel gene therapies targeting refractory malignancies has led to research that extends this technology to a variety of infectious and rheumatological diseases. Unlike conventional drugs or antibodies, T cells have the potential to target and exert effector function in response to disease in a dynamic manner, acting as a “living drug”. The most efficacious form of gene-modified T cells to date is the chimeric antigen receptor (CAR)-modified T cell, which redirects the specificity of T cells to an antigen expressed by tumor cells. Clinical experience with autologous CAR-T cells, primarily in hematologic malignancies, has underscored the feasibility and safety of the approach, while also demonstrating dramatic and sustained antitumor effects through mechanisms orthogonal to those of traditional anticancer therapies. However, several challenging obstacles must be surmounted in order to improve the broader efficacy of this approach. |
| car t cell therapy janssen: Pleural Disease Nick Maskell, 2020 This Monograph provides the clinician with an up-to-date summary of the substantial evidence in our understanding of pleural disease. It covers key aspects relevant to clinicians, including mechanisms, pathophysiology, epidemiology, diagnostics, relevant experimental models and interventions. Although broad in scope, readers will be able to reach into individual chapters to gain a focused summary of specific areas relevant to their clinical or scientific practice. |
| car t cell therapy janssen: Life Science Unicorns, from a China Investment Perspective Da LIU（柳達）, 2023-06-27 This book systematically expounds the history of the global pharmaceutical industry in the past 50 years, adopts the philosophical theory of paradigm and paradigm shift, analyzes the current investment hot areas, and predicts potential “life sciences unicorns”. Written by many industry opinion leaders, this book is a rare professional work that combines practice with theory, combines Chinese characteristics with a global perspective, and combines business with science. With the purpose of popularizing knowledge and education, this book uses a large number of cases, introductions, recommended books and report catalogs, so that readers can learn and think systematically and comprehensively. |
| car t cell therapy janssen: Biopharma in China Sven Agten, |
| car t cell therapy janssen: Critical Developments in Cancer Immunotherapy Sheykhhasan, Mohsen, Yang, Piao, Poondla, Naresh, 2024-08-28 Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes. Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment. |
| car t cell therapy janssen: Ex Vivo Cell Therapy Klaus Schindhelm, Robert Nordon, 1999 R.E. Nordon and K. Schindhelm, Introduction. -- L. Robb, A.G. Elefanty, and C.G. Begley, Transcriptional Control of Hematopoieses. -- R. Starr and N.A. Nicola, Cell Signaling by Hemopoietic Growth Factor Receptors. -- P.J. Simmons, D.N. Haylock, and J.-P. Lévesque, Influence of Cytokines and Adhesion Molecules on Hematopoietic Stem Cell Development. -- P.A. Rowlings, Allogeneic Hematopoietic Stem Cell Transplantation. -- U. Hahn and L.B. To, Autologous Stem Cell Transplantation. -- M.R. Vowels, Cord Blood Stem Cell Transplantation. -- S.R. Riddell, E.H. Warren, D. Lewinsohn, C. Yee, and P.D. Greenberg, Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. -- L.Q. Sun, M. Miller, and G. Symonds, Exogenous Gene Transfer into Lymphoid and Hematopoietic Progenitor Cells. -- C. Dowding, T. Leemhuis, A. Jakubowski, and C. Reading, Process Development for Ex Vivo Cell Therapy. -- R.E. Nordon and K. Schindhelm, Cell Separation. -- P.W. Zandstra, C.J. Eaves, and J.M. Piret, Environ ... |
| car t cell therapy janssen: Advances in Cancer Research , 2024-09-19 the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research, with this updated edition covering chapters on A bioinformatic-driven prediction of MDA9 transcriptional variants' roles in cancer progression and treatment, Redox, cysteines, and kinases - A triad sustaining myeloid leukemia, The RAF cysteine-rich domain: structure, function, and role in disease , Membrane Potential: a new hallmark of cancer, Recent Advances and Progress in Immunotherapy of Solid Cancers, and much more.Other sections explore Precision Medicine: Non-Invasive Therapeutic Agent Delivery with Focused Ultrasound and Microbubbles and Anti-Cancer Activity of Capsaicin and its Analogs in Gynecological Cancers. - Provides the latest information on cancer research - Offers outstanding and original reviews on a range of cancer research topics - Serves as an indispensable reference for researchers and students alike |
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
r/Cars - For Car Enthusiasts - Reddit
r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY guides, advice, stories, …
Former CarMax employee here. If you plan to go in for an ... - Reddit
Feb 3, 2021 · Where younger an estimated value and when you come in our car buyer puts in his notes and we show you side by side. Where you thought you were and didn't mention that …
How much do car salesmen REALLY make? : r/askcarsales - Reddit
Apr 26, 2022 · Is 6 figures in car sales the norm? EDIT: 25M, single, no kids. Currently in civil engineering with $78k salary in LCOL area (central texas). Seems like folks are making well …
Hoseheadforums.com Home
Aug 17, 2013 · Bodnar Motorsports building new car for 2019 viewed (10751) Wicked Energy Gum to Sponsor the Northwest Focus Midget Series viewed (8765) Heartland Motorsports Park …
best places to search for used cars : r/cars - Reddit
Sep 7, 2018 · r/Cars is the largest automotive enthusiast community on the Internet. We're Reddit's central hub for vehicle-related discussion, industry news, reviews, projects, DIY …
Car dealership scratch-off mailer scam (Update) : r/Scams - Reddit
Mar 12, 2019 · I posted a couple of days ago about a scratch-off contest mailer that I had received from a local car dealership. My "game piece" seemed to indicate that I had won the Grand …
Nothing Under - Reddit
r/NothingUnder: Dresses and clothing with nothing underneath. Women in outfits perfect for flashing, easy access, and teasing men.
What’s the best auto insurance? : r/Insurance - Reddit
I also know that being young and driving a newer car is the reason behind all this, but any advice/tips about all this is much needed! Is the monthly rate really normal for someone my …
HoseHeads Sprint Car General Forum - Oval Track Racing Forums
4 days ago · Forum: HoseHeads Sprint Car General Forum Moderators: dirtonly / dmantx / hosehead First
I've been scouring the internet for a working download link to
Aug 26, 2023 · 31 votes, 30 comments. 36K subscribers in the E90 community. Hub for all BMW 3 series, 2006-2013. Anyone is welcome!
